Visi-Jet

**Chris Ryser** · 02-04-2005, 04:56 AM

VisiJet, Inc. Completes $4.9 Million Financing
Wed Feb 2, 2005 4:22 AM ET

IRVINE, Calif.--(BUSINESS WIRE)--Feb. 2, 2005--VisiJet, Inc. (OTCBB: VJET), a developer of innovative technologies for the ophthalmic surgical market, has closed on a financing of $4.9 million. VisiJet plans to use the funds to support marketing and sales of its lead product, the EpiLift System, and to improve its short-term debt structure. The EpiLift System is a new, safer refractive surgery technique that enables ophthalmologists to perform EpiLASIK surgery with fewer postoperative complications than existing methods. Six firms participated in the financing, including Renaissance Capital, Corsair Capital, Roaring Fork Capital Management, Alpha Capital AG, Little Gem Life Sciences, and Liberty View Capital.

"This financing gives VisiJet the resources to make the EpiLift system widely available and drive sales growth, " said Bob Pearson, Senior Vice President at Renaissance Capital. "The FDA approved, EpiLift product is a strong offering in the refractive surgery space, and is already gaining traction in the market."

"The financing comes at an opportune time for VisiJet. We received FDA approval for the Epilift system in September 2004, and with this round of financing, the company will have the ability to fund a sales and marketing program to support this unique product. We are determined to build a sales team with the ability and focus to drive the rollout both in the United States and internationally," "said Randy Bailey, CEO of VisiJet Inc.

About VisiJet

VisiJet, Inc. is a medical device company based in Irvine, California, focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in LASIK surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. Gebauer Medizintechnik GmbH of Germany manufactures the EpiLift system.

In addition to the EpiLift system, VisiJet is developing HydroKeratome(R) and Pulsatome(R), which utilize the company's proprietary and patented waterjet technology. These products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. HydroKeratome(R) uses the waterjet technology, employing a high-pressure micro beam of water with the diameter of a human hair to cut the corneal flap as required in LASIK surgery. The Pulsatome(R) cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts - the most frequently performed surgical procedure in the world.

This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings. --30--AH/ny*

**esf1** · 02-24-2006, 07:52 PM

This company is now Advanced Refractive technologies. They are working on a product called pulsatome for cataract surgery. Last year it was huge this year nothing the stock is only $0.02, Does anyone know anything about this????

**AWTECH** · 02-25-2006, 01:30 AM

I am always skeptical of a deal like this, 6 investment houses in a $4.9 million deal? If the technology is this good why wouldn't one of the capital houses be able to invest the total. Unfortunately OTCBB companies are plagued with a continuing history of pump and dump no matter what you hear.

Is this a German designed and built system that this company got FDA approval for use in the US? This was FDA approved in 2004. No mention of any sales test results success or a definitive plan. It could be that other system can do the same job, no mention of competition.

I would not speculate on the stock.